Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials-Reference-Cited by-同舟云学术

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

Published:2018-08-09 Issue:8 Volume:4 Page:e180798
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

O’Connor Jeremy M.¹²,Fessele Kristen L.³,Steiner Jean³,Seidl-Rathkopf Kathi³,Carson Kenneth R.³,Nussbaum Nathan C.³,Yin Emily S.¹,Adelson Kerin B.¹⁴,Presley Carolyn J.⁵,Chiang Anne C.¹⁴,Ross Joseph S.¹²,Abernethy Amy P.³,Gross Cary P.¹²

Affiliation:

1. Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

2. National Clinician Scholars Program, Yale University School of Medicine, New Haven, Connecticut

3. Flatiron Health Inc, New York, New York

4. Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut

5. The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference65 articles.

1. AACR Cancer Progress Report 2016.;Davidson;Clin Cancer Res,2016

2. A U.S. “Cancer Moonshot” to accelerate cancer research.;Singer;Science,2016

3. The 21st Century Cures Act: will it take us back in time?;Avorn;N Engl J Med,2015

4. Regulatory review of novel therapeutics: comparison of three regulatory agencies.;Downing;N Engl J Med,2012

5. The answer is 17 years, what is the question: understanding time lags in translational research.;Morris;J R Soc Med,2011

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC;Immunotherapy;2024-09-13

2. The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer;Cancer Immunology, Immunotherapy;2024-07-02

3. Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer;Cancers;2024-06-07

4. Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor;PLOS ONE;2024-06-05

5. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer;BMC Cancer;2024-04-06